

ASX Release

Issue of Tranche 2 Placement Shares

ADELAIDE, 26 November 2025: Anatara Lifesciences Limited (ASX:ANR) ("**Anatara**" or the "**Company**") advises that it has today completed the final allocation under Tranche 2 of the two tranche placement announced on 1 October 2025 (**Tranche 2 Placement Shares**).

Details of the Tranche 2 Placement Shares are provided below:

Class of Securities	Ordinary Shares
Total number of Shares	66,352,417
ASX Code of the securities	ASX: ANR

The Company also confirms the allotment of 4,000,000 unlisted Options exercisable at \$0.025 each and expiring 3 years from issue to the Lead Manager to the Placement, as approved by Shareholders at the Company's Annual General Meeting on 20 November 2025.

Cleansing Notice

In accordance with section 708A(6) of the *Corporations Act* (Cth) (**Corporations Act**) Anatara gives notice under section 708A(5)(e) of the *Corporations Act* that:

- the Tranche 2 Placement Shares were issued without disclosure to investors under Part 6D.2 of the *Corporations Act*;
- this notice is being given under section 708A(5)(e) of the *Corporations Act*;
- as of the date of this notice, the Company has complied with:
 - the provisions of Chapter 2M of the *Corporations Act* as they apply to the Company; and
 - sections 674 and 674A of the *Corporations Act*; and
- as of the date of this notice, there is no "excluded information" as defined in sections 708A(7) and 708A(8) of the *Corporations Act* which is required to be disclosed by the Company.

This announcement has been approved by the Board of Anatara Lifesciences Limited.



For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited
Registered Office
C/-PERKS Level 8, 81 Flinders Street, Adelaide SA 5000
Email info@anatara.com | Website anataralifesciences.com

